April 10, 2017

Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma  Read more   Download

July 25, 2016

BioCentury Emerging Company Profile of Alexo Therapeutics  Read article


Cambridge Healthtech Institute’s 15th Annual Discovery on Target: Targeting Tumor Myeloid Cells

September 28, 2017, 11:20 am ET – Boston, MA

Targeting CD47 with High-Affinity SIRPα Fusion Protein to Enhance Both Innate and Adaptive Immunity Against Cancer Without Hematological Toxicity

Presenter: Hong I. Wan, Ph.D., Alexo Therapeutics, Chief Scientific Officer

32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

November 10, 2017, 12:30-2:00 pm ET – National Harbor, MD

Poster P241: A First-in-Human Study of ALX148: CD47 Blockade to Enhance Innate and Adaptive Immunity for Advanced Solid Tumor Malignancy and Non Hodgkin Lymphoma